Impact of 18F-FDG PET on the management of recurrent breast cancer: a meta-analysis
Purpose The incidence of breast cancer has increased steadily. We performed a meta-analysis to assess the impact of 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the management of breast cancer with respect to the detection of recurrence/metastasis after curative surgery. Metho...
Gespeichert in:
| Veröffentlicht in: | Clinical and translational imaging : reviews in nuclear medicine and molecular imaging 2021-06, Vol.9 (3), p.255-263 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 263 |
|---|---|
| container_issue | 3 |
| container_start_page | 255 |
| container_title | Clinical and translational imaging : reviews in nuclear medicine and molecular imaging |
| container_volume | 9 |
| creator | Pak, Kyoungjune Yoon, Hai-Jeon Lim, Woosung Kim, Hyun Yul |
| description | Purpose
The incidence of breast cancer has increased steadily. We performed a meta-analysis to assess the impact of
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the management of breast cancer with respect to the detection of recurrence/metastasis after curative surgery.
Methods
We performed systematic searches of the MEDLINE and EMBASE databases for English language publications. All published studies regarding the impact of PET on the management of patients with breast cancer with respect to the detection of recurrence/metastasis after curative surgery, such as mastectomy or lumpectomy, were searched. The proportion of management change (%), defined as the percentage of patients for whom management was changed after FDG PET among patients who underwent FDG PET, was calculated.
Results
Thirteen studies, which included 982 patients, were included in this study. The impact of PET was evaluated based on the proportion of management change, and a pooled effect of 44.4% was noted. In the subgroup analyses for (1) equivocal/suspicious recurrence/metastasis on conventional imaging, (2) abnormal symptoms or physical examination, and (3) elevated tumor markers (
n
= 834), the pooled rate of management change was 45.9%. In patients with elevated tumor markers (
n
= 350) and in those who underwent PET for routine surveillance, the pooled rates of management change were 52.3% and 12.4%, respectively.
Conclusions
18
F-FDG PET has a major impact on the management of patients with breast cancer after curative surgery. These findings suggest that
18
F-FDG PET should be performed in patients with breast cancer in cases involving equivocal or suspicious recurrence/metastasis on conventional imaging or in cases involving elevated tumor markers during follow-up. However, this study does not support the routine use of
18
F-FDG PET for surveillance in breast cancer. |
| doi_str_mv | 10.1007/s40336-021-00424-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2535299844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2535299844</sourcerecordid><originalsourceid>FETCH-LOGICAL-c249t-8f5a29c7d5f51e3de3d9be0ed14ecdfdc1e0506d8020fa470a48fd940a2777af3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWGr_gKeA5-hMNml2vUlta6GgYD2HNDupLd3dmmwP_fduP8CbMDAz8LzD8DB2j_CIAOYpKciyoQCJAkBJJfCK9aTMURg91NeXWedG3rJBShsAQECNiD32Oat2zre8CRzziZi8TvnHeMGbmrffxCtXuxVVVJ-ASH4f43FZRnKp5d7VnuIzd7yi1okO3h7SOt2xm-C2iQaX3mdfk_Fi9Cbm79PZ6GUuvFRFK_KgnSy8KXXQSFnZVbEkoBIV-TKUHgk0DMscJASnDDiVh7JQ4KQxxoWszx7Od3ex-dlTau2m2cfuiWSlzrQsilypjpJnyscmpUjB7uK6cvFgEezRnz37s50_e_JnsQtl51Dq4HpF8e_0P6lfhMVxQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2535299844</pqid></control><display><type>article</type><title>Impact of 18F-FDG PET on the management of recurrent breast cancer: a meta-analysis</title><source>SpringerLink (Online service)</source><creator>Pak, Kyoungjune ; Yoon, Hai-Jeon ; Lim, Woosung ; Kim, Hyun Yul</creator><creatorcontrib>Pak, Kyoungjune ; Yoon, Hai-Jeon ; Lim, Woosung ; Kim, Hyun Yul</creatorcontrib><description>Purpose
The incidence of breast cancer has increased steadily. We performed a meta-analysis to assess the impact of
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the management of breast cancer with respect to the detection of recurrence/metastasis after curative surgery.
Methods
We performed systematic searches of the MEDLINE and EMBASE databases for English language publications. All published studies regarding the impact of PET on the management of patients with breast cancer with respect to the detection of recurrence/metastasis after curative surgery, such as mastectomy or lumpectomy, were searched. The proportion of management change (%), defined as the percentage of patients for whom management was changed after FDG PET among patients who underwent FDG PET, was calculated.
Results
Thirteen studies, which included 982 patients, were included in this study. The impact of PET was evaluated based on the proportion of management change, and a pooled effect of 44.4% was noted. In the subgroup analyses for (1) equivocal/suspicious recurrence/metastasis on conventional imaging, (2) abnormal symptoms or physical examination, and (3) elevated tumor markers (
n
= 834), the pooled rate of management change was 45.9%. In patients with elevated tumor markers (
n
= 350) and in those who underwent PET for routine surveillance, the pooled rates of management change were 52.3% and 12.4%, respectively.
Conclusions
18
F-FDG PET has a major impact on the management of patients with breast cancer after curative surgery. These findings suggest that
18
F-FDG PET should be performed in patients with breast cancer in cases involving equivocal or suspicious recurrence/metastasis on conventional imaging or in cases involving elevated tumor markers during follow-up. However, this study does not support the routine use of
18
F-FDG PET for surveillance in breast cancer.</description><identifier>ISSN: 2281-5872</identifier><identifier>EISSN: 2281-7565</identifier><identifier>DOI: 10.1007/s40336-021-00424-1</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biomarkers ; Breast cancer ; Diagnostic Radiology ; Emission analysis ; Fluorine isotopes ; Imaging ; Interventional Radiology ; Markers ; Medical and Radiation Physics ; Medical imaging ; Medicine ; Medicine & Public Health ; Meta-Analysis ; Metastasis ; Nuclear Medicine ; Oncology ; Positron emission ; Radiology ; Radiotherapy ; Subgroups ; Surgery ; Surveillance ; Tomography ; Tumors</subject><ispartof>Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2021-06, Vol.9 (3), p.255-263</ispartof><rights>Italian Association of Nuclear Medicine and Molecular Imaging 2021. corrected publication 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c249t-8f5a29c7d5f51e3de3d9be0ed14ecdfdc1e0506d8020fa470a48fd940a2777af3</citedby><cites>FETCH-LOGICAL-c249t-8f5a29c7d5f51e3de3d9be0ed14ecdfdc1e0506d8020fa470a48fd940a2777af3</cites><orcidid>0000-0001-5051-1894</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40336-021-00424-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40336-021-00424-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids></links><search><creatorcontrib>Pak, Kyoungjune</creatorcontrib><creatorcontrib>Yoon, Hai-Jeon</creatorcontrib><creatorcontrib>Lim, Woosung</creatorcontrib><creatorcontrib>Kim, Hyun Yul</creatorcontrib><title>Impact of 18F-FDG PET on the management of recurrent breast cancer: a meta-analysis</title><title>Clinical and translational imaging : reviews in nuclear medicine and molecular imaging</title><addtitle>Clin Transl Imaging</addtitle><description>Purpose
The incidence of breast cancer has increased steadily. We performed a meta-analysis to assess the impact of
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the management of breast cancer with respect to the detection of recurrence/metastasis after curative surgery.
Methods
We performed systematic searches of the MEDLINE and EMBASE databases for English language publications. All published studies regarding the impact of PET on the management of patients with breast cancer with respect to the detection of recurrence/metastasis after curative surgery, such as mastectomy or lumpectomy, were searched. The proportion of management change (%), defined as the percentage of patients for whom management was changed after FDG PET among patients who underwent FDG PET, was calculated.
Results
Thirteen studies, which included 982 patients, were included in this study. The impact of PET was evaluated based on the proportion of management change, and a pooled effect of 44.4% was noted. In the subgroup analyses for (1) equivocal/suspicious recurrence/metastasis on conventional imaging, (2) abnormal symptoms or physical examination, and (3) elevated tumor markers (
n
= 834), the pooled rate of management change was 45.9%. In patients with elevated tumor markers (
n
= 350) and in those who underwent PET for routine surveillance, the pooled rates of management change were 52.3% and 12.4%, respectively.
Conclusions
18
F-FDG PET has a major impact on the management of patients with breast cancer after curative surgery. These findings suggest that
18
F-FDG PET should be performed in patients with breast cancer in cases involving equivocal or suspicious recurrence/metastasis on conventional imaging or in cases involving elevated tumor markers during follow-up. However, this study does not support the routine use of
18
F-FDG PET for surveillance in breast cancer.</description><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Diagnostic Radiology</subject><subject>Emission analysis</subject><subject>Fluorine isotopes</subject><subject>Imaging</subject><subject>Interventional Radiology</subject><subject>Markers</subject><subject>Medical and Radiation Physics</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-Analysis</subject><subject>Metastasis</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Positron emission</subject><subject>Radiology</subject><subject>Radiotherapy</subject><subject>Subgroups</subject><subject>Surgery</subject><subject>Surveillance</subject><subject>Tomography</subject><subject>Tumors</subject><issn>2281-5872</issn><issn>2281-7565</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMoWGr_gKeA5-hMNml2vUlta6GgYD2HNDupLd3dmmwP_fduP8CbMDAz8LzD8DB2j_CIAOYpKciyoQCJAkBJJfCK9aTMURg91NeXWedG3rJBShsAQECNiD32Oat2zre8CRzziZi8TvnHeMGbmrffxCtXuxVVVJ-ASH4f43FZRnKp5d7VnuIzd7yi1okO3h7SOt2xm-C2iQaX3mdfk_Fi9Cbm79PZ6GUuvFRFK_KgnSy8KXXQSFnZVbEkoBIV-TKUHgk0DMscJASnDDiVh7JQ4KQxxoWszx7Od3ex-dlTau2m2cfuiWSlzrQsilypjpJnyscmpUjB7uK6cvFgEezRnz37s50_e_JnsQtl51Dq4HpF8e_0P6lfhMVxQQ</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Pak, Kyoungjune</creator><creator>Yoon, Hai-Jeon</creator><creator>Lim, Woosung</creator><creator>Kim, Hyun Yul</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-5051-1894</orcidid></search><sort><creationdate>20210601</creationdate><title>Impact of 18F-FDG PET on the management of recurrent breast cancer: a meta-analysis</title><author>Pak, Kyoungjune ; Yoon, Hai-Jeon ; Lim, Woosung ; Kim, Hyun Yul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c249t-8f5a29c7d5f51e3de3d9be0ed14ecdfdc1e0506d8020fa470a48fd940a2777af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Diagnostic Radiology</topic><topic>Emission analysis</topic><topic>Fluorine isotopes</topic><topic>Imaging</topic><topic>Interventional Radiology</topic><topic>Markers</topic><topic>Medical and Radiation Physics</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-Analysis</topic><topic>Metastasis</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Positron emission</topic><topic>Radiology</topic><topic>Radiotherapy</topic><topic>Subgroups</topic><topic>Surgery</topic><topic>Surveillance</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pak, Kyoungjune</creatorcontrib><creatorcontrib>Yoon, Hai-Jeon</creatorcontrib><creatorcontrib>Lim, Woosung</creatorcontrib><creatorcontrib>Kim, Hyun Yul</creatorcontrib><collection>CrossRef</collection><jtitle>Clinical and translational imaging : reviews in nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pak, Kyoungjune</au><au>Yoon, Hai-Jeon</au><au>Lim, Woosung</au><au>Kim, Hyun Yul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of 18F-FDG PET on the management of recurrent breast cancer: a meta-analysis</atitle><jtitle>Clinical and translational imaging : reviews in nuclear medicine and molecular imaging</jtitle><stitle>Clin Transl Imaging</stitle><date>2021-06-01</date><risdate>2021</risdate><volume>9</volume><issue>3</issue><spage>255</spage><epage>263</epage><pages>255-263</pages><issn>2281-5872</issn><eissn>2281-7565</eissn><abstract>Purpose
The incidence of breast cancer has increased steadily. We performed a meta-analysis to assess the impact of
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the management of breast cancer with respect to the detection of recurrence/metastasis after curative surgery.
Methods
We performed systematic searches of the MEDLINE and EMBASE databases for English language publications. All published studies regarding the impact of PET on the management of patients with breast cancer with respect to the detection of recurrence/metastasis after curative surgery, such as mastectomy or lumpectomy, were searched. The proportion of management change (%), defined as the percentage of patients for whom management was changed after FDG PET among patients who underwent FDG PET, was calculated.
Results
Thirteen studies, which included 982 patients, were included in this study. The impact of PET was evaluated based on the proportion of management change, and a pooled effect of 44.4% was noted. In the subgroup analyses for (1) equivocal/suspicious recurrence/metastasis on conventional imaging, (2) abnormal symptoms or physical examination, and (3) elevated tumor markers (
n
= 834), the pooled rate of management change was 45.9%. In patients with elevated tumor markers (
n
= 350) and in those who underwent PET for routine surveillance, the pooled rates of management change were 52.3% and 12.4%, respectively.
Conclusions
18
F-FDG PET has a major impact on the management of patients with breast cancer after curative surgery. These findings suggest that
18
F-FDG PET should be performed in patients with breast cancer in cases involving equivocal or suspicious recurrence/metastasis on conventional imaging or in cases involving elevated tumor markers during follow-up. However, this study does not support the routine use of
18
F-FDG PET for surveillance in breast cancer.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s40336-021-00424-1</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-5051-1894</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2281-5872 |
| ispartof | Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2021-06, Vol.9 (3), p.255-263 |
| issn | 2281-5872 2281-7565 |
| language | eng |
| recordid | cdi_proquest_journals_2535299844 |
| source | SpringerLink (Online service) |
| subjects | Biomarkers Breast cancer Diagnostic Radiology Emission analysis Fluorine isotopes Imaging Interventional Radiology Markers Medical and Radiation Physics Medical imaging Medicine Medicine & Public Health Meta-Analysis Metastasis Nuclear Medicine Oncology Positron emission Radiology Radiotherapy Subgroups Surgery Surveillance Tomography Tumors |
| title | Impact of 18F-FDG PET on the management of recurrent breast cancer: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A40%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%2018F-FDG%20PET%20on%20the%20management%20of%20recurrent%20breast%20cancer:%20a%20meta-analysis&rft.jtitle=Clinical%20and%20translational%20imaging%20:%20reviews%20in%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Pak,%20Kyoungjune&rft.date=2021-06-01&rft.volume=9&rft.issue=3&rft.spage=255&rft.epage=263&rft.pages=255-263&rft.issn=2281-5872&rft.eissn=2281-7565&rft_id=info:doi/10.1007/s40336-021-00424-1&rft_dat=%3Cproquest_cross%3E2535299844%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2535299844&rft_id=info:pmid/&rfr_iscdi=true |